Skip to content
drillr.ai
Sign up

QNRX

Quoin Pharmaceuticals, Ltd.

NASDAQ · Healthcare · Biotechnology · US

$7.26
−7.75%
Ask drillr

  • Aug 28, 2026, 13:40 UTC

    Quoin Pharmaceuticals announced positive clinical trial results for its product on Friday morning.

    Source:

  • Aug 28, 2026, 10:00 UTC

    Quoin Pharmaceuticals entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds through a private placement of ordinary shares and warrants.

    Source:

  • Aug 20, 2026, 00:00 UTC

    Quoin Pharmaceuticals, Ltd. elected Dr. Michael Myers, Denise Carter, Joseph Cooper, James Culverwell, and Dr. Dennis H. Langer as directors, effective August 20, 2026.

  • Aug 14, 2026, 12:30 UTC

    Quoin Pharmaceuticals received FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome, received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, and submitted an IND for Peeling Skin Syndrome with FDA clearance received after quarter end.

    Source:

  • Aug 14, 2026, 00:00 UTC

    Quoin Pharmaceuticals reported a net loss of approximately $5.4 million for Q2 2026, with diluted EPS of -$1.90, and a net loss of approximately $10.4 million for the first half of 2026.

  • Aug 7, 2026, 12:30 UTC

    Quoin Pharmaceuticals announced it will release its second quarter 2026 financial results and provide a corporate update on August 14, 2026.

    Source:

  • Jun 30, 2026, 12:30 UTC

    Quoin Pharmaceuticals received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome.

    Source:

  • Jun 18, 2026, 12:30 UTC

    Quoin Pharmaceuticals completed the establishment of a Japanese subsidiary to advance commercial readiness for QRX003.

    Source:

  • Jun 5, 2026, 05:57 UTC

    Quoin Pharmaceuticals received orphan drug designation for QRX003 from Japan's Ministry of Health, Labour and Welfare for treating Netherton Syndrome.

    Source:

  • Jun 2, 2026, 12:30 UTC

    Quoin Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA for QRX003 to treat Peeling Skin Syndrome.

    Source: